Regeneron's bispecific for lymphoma works in CAR-T failures

REGN1979 is in a race to market with a rival CD20/CD3 bispecific antibody being developed by Roche. ... Roche’s mosunetuzumab candidate showed activity in relapsed/refractory B-cell indolent and aggressive NHL in a phase 1/2 trial reported at the

Syncona start-up Quell Therapeutics appoints chief exec

Prior to that, he had served in various senior roles in positions in transplantation and immunology for Wyeth, Novartis and Roche.

Targacept picks Solvay's Stephen Hill to fill vacant CEO post

Prior to that, he served at US biotech ArQule and Roche, where he held several leadership positions including global head of clinical development.

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]